Tufts study finds AI can accelerate cancer drug trials and cut costs

A new Tufts Center for the Study of Drug Development analysis shows AI agents can shorten late-stage cancer drug clinical development by about 10 weeks and reduce direct operating costs by up to $5.6 million.

• AI agents accelerate clinical development of cancer drugs by approximately 10 weeks.
• Direct operating costs can be reduced by up to $5.6 million in late-stage trials.
• Efficiencies scale with the number of tumors a drug can target.